In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Pharmaceutical Industries Ltd.

Latest From Teva Pharmaceutical Industries Ltd.

Talks Must Start Now On New Irish Drug Supply Pact

An industry group representing Ireland’s generic-and-biosimilar makers says talks “need to start now” on a new national medicine supply accord to create more affordable access to life-saving drugs, with the association’s members at the negotiating table.

Ireland Regulation

Drug Pricing Hearing Takes A Partisan Turn As Gilead’s O’Day Holds His Own

Republicans took off the gloves at House oversight hearing on PrEP, arguing Democrats are more interested in scoring political points than seeking policy solutions to high drug costs.
Pricing Debate Legislation

Teva Takes A Further Hit On Value Of Actavis

Teva has registered a further impairment of almost $500m, largely linked to the value of assets acquired when it took over Actavis in 2016. Meanwhile, sales slid by 15% to $4.3bn in the first quarter.

Sales & Earnings Strategy

Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy
See All

Company Information